Canine lymphoma is a heterogeneous group of diseases and many previous studies have evaluated the response of a mixed population of lymphoma cases to one specific treatment protocol.
Canine lymphoma is a heterogeneous group of diseases and many previous studies have evaluated the response of a mixed population of lymphoma cases to one specific treatment protocol.
The aim of this retrospective study was to describe the outcome and prognostic factors in 42 cases of multicentric centroblastic diffuse large B-cell lymphoma treated with either a COPtype (35%) or CHOP-type (64%) induction chemotherapy. The objective response rate to induction therapy was 94%; entire dogs had a greater rate of complete vs partial remissions than neutered dogs (P = .017). Median progression-free survival for the first remission (PFS1) was 182 days; absence of anaemia at diagnosis (P = .002) and pretreatment neutrophil:lymphocyte ratio (NLR) below 9.44 (P = .015) were independently predictive of longer PFS1. Fiftyeight percent of dogs received rescue protocols with an objective response rate of 81%; 31% of dogs received further rescue protocols (up to a total of 5) and the median number of protocols administered were 2. Median overall survival (OS) was 322 days, the 1-year survival rate was 38% and the 2-year survival rate was 9%. Lymphocyte:monocyte ratio above 1.43 (P = .031), NLR below 11.44 (P = .009), the combination of induction and rescue therapy (P = .030) and the total number of doxorubicin doses used (P = .002) were independently predictive of longer OS. Use of a COP-type protocol induction compared with CHOP did not undermine OS providing doxorubicin was used as rescue therapy.
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| INTRODUCTION
Canine lymphoma (CL) is one of the most prevalent cancers in dogs and the most prevalent haematopoietic cancer.
1 B-cell immunophenotype and multicentric distribution of disease are the most common presentations. [2] [3] [4] CL is considered to be an analogue of the human, non-Hodgkin's lymphoma (NHL), 5, 6 and both the World Health Organization (WHO) and updated Kiel morphological classifications of NHL have been shown to apply to CL. 7, 8 Since the common morphological subtypes of CL involve diffuse effacement of lymph node architecture with a monotypic population of lymphocytes, cytological review of fine needle aspirate samples is considered a sensitive and specific means of diagnosis, 7, 9, 10 and is the most commonly used method of diagnosis. 11 Furthermore, cytology has been shown to be a reliable means of applying both the updated Kiel system of morphological classification 8, 10, 12, 13 and the WHO classification. [14] [15] [16] The most prevalent cytomorphological subtype of CL (WHO classification) is diffuse large B-cell lymphoma (DLBCL), reported to represent 48% of cases in dogs, 7 and DLBCL can be subdivided in accordance with the Kiel classification into the centroblastic subtype (representing approximately 77% of cases), and the immunoblastic subtype (representing approximately 23% of cases). 7 Traditionally, outcome for CL has been described in the light of treatment with different chemotherapy protocols. When treated with COP-type protocols, CL cases have been reported to have a median first remission duration of 3 to 6 months and a 19% 1-year survival rate, 17, 18 whereas those treated with a CHOP protocol have been reported to have a first remission duration of 8.4 to 11 months and a 1-year survival rate of 50%. [19] [20] [21] [22] Nevertheless, these studies have been based on populations of heterogeneous cytomorphological subtypes of CL, and recent studies have shown that heterogeneity in these populations may be a significant confounding factor where prognosis is concerned. Ponce et al 13 demonstrated significant differences in survival between small groups of dogs with different cytomorphological subtypes of CL (using the Kiel classification) and Valli et al 23 later
repeated and expanded these observations using the WHO classification of histological samples. 23 Thus, the response of dogs with specific cytomorphological subtypes of CL to one of the chemotherapy protocols consistently used in the literature is difficult to predict.
Aside from treatment protocol and cytomorphological subtype, many consistent prognostic factors for CL have been reported, for example, WHO clinical substage, 19, 24, 25 immunophenotype, [26] [27] [28] [29] [30] histopathological grade, 24, 29, 31 anatomical location of disease [32] [33] [34] [35] and presence of anaemia at diagnosis. 29, 36 Other factors such as WHO stage of disease have shown prognostic significance in some studies, 17, 37 but not others. 38 Many other features associated with a dog's presentation may also be of prognostic value, but have been less well-evaluated. In human medicine, the pretreatment absolute monocyte concentration (AMC), 39 absolute lymphocyte concentration (ALC) 40 and the neutrophil:lymphocyte ratio (NLR) 41 have been found to be highly predictive of prognosis in DLBCL. Other parameters, for example, the pretreatment absolute neutrophil concentration (ANC) and lymphocyte:monocyte ratio (LMR) have found prognostic significance in other solid tumours. 42, 43 In veterinary medicine, AMC 44 and LMR 45 have been found to be of prognostic value in lymphoma, whereas the NLR has not been found to affect prognosis. 46 Pretreatment ANC has been found to be prognostic in acute leukaemia, 47 and both AMC and ALC have been found to be prognostic in canine osteosarcoma. 48 The diagnostic utility of NLR in differentiating soft tissue sarcomas from benign neoplasms, 49 and identifying bone marrow involvement in canine mast cell disease has been suggested. 50, 51 The aim of this study was to describe the clinical presentation, response to treatment, progression-free survival (PFS) and overall survival (OS) of a homogenous group of dogs with multicentric, centroblastic diffuse large B-cell lymphoma (mDLBCL-CB) treated with standardized induction and rescue chemotherapy protocols, and to identify prognostic factors associated with this cytomorphological type of CL. Since heterogeneous groups of CL contain cases with established negative prognostic factors (eg, T-cell immunophenotype, cutaneous and hepatosplenic presentations), the hypothesis was that a homogenous group of mDLBCL-CB cases will have a longer PFS and OS than a heterogeneous population of CL cases. the time from the administration of the first lymphoma treatment (cytotoxic drug, glucocorticoids or l-asparaginase), to disease relapse, progression or death from any cause; PFS1 was used to denote the PFS for the first remission, PFS2 for the second, and so forth. Dogs that had treatment changed for reasons other than disease progression (eg, due to patient's demeanour) were censored from PFS analysis at the point the treatment was altered. OS was defined as the time between the administration of the first lymphoma treatment and death or euthanasia. 54 Dogs that remained alive at the end of the follow-up period or that were lost to follow-up were censored from OS analysis.
| MATERIALS AND METHODS

| Study population
| Statistical analysis
Data were described and analysed using SPSS version 22 (IBM corp., Armonk, NY, USA) and Graphpad Prism version 6 (Graphpad Software Inc., San Diego, CA, USA). Data were assessed for normality by visual plotting and use of the Shapiro-Wilk test. Univariable analysis of response to treatment was performed using binary logistic regression; Log-rank and Cox proportional hazard regression were used to analyse the effect of multiple variables on PFS and OS. Where analyses of different treatment protocols were performed, the CHOP or doxorubicin-based groups were used as the comparator, given the acceptance of doxorubicin-based protocols as the standard of care
for CL therapy. 20 The alpha level was set at P = .05 for significance.
Receiver operating characteristic (ROC) curve analysis was performed to assign cut-off values to continuous variables used for the prediction of a PFS or OS exceeding a certain time, usually its median value; a minimum area under the curve of 0.7 was required for the ROC model to be considered. Comparison of groups with different survival times was performed using Fisher's exact test for categorical variables. Student's (2-tailed) t test and Mann-Whitney U test for parametric and non-parametric continuous variables, respectively.
3 | RESULTS
| Clinical presentation
Search results revealed 91 cases of canine B-cell lymphoma; out of these, 65 cases of multicentric CL were identified and 45 dogs were Haematology findings from before the administration of anticancer treatment (including steroids or l-asparaginase) were available for 29 dogs. Eleven dogs (38%) were anaemic (median PCV 33%, range 29%-37%, all non-regenerative or insufficiently regenerative), 7 dogs (24%) had a neutrophilia, 12 dogs (41%) were lymphopenic, 1 dog (3%) had monocytosis and 1 dog (3%) had a lymphocytosis. Median absolute leukocyte concentrations and ratios are displayed in Table 1 .
Pretreatment serum biochemistry and urinalysis were available for 35 dogs; 10 (29%) had biochemical abnormalities, the most common of which were hyperbilirubinaemia and increased activities of serum ALT and ALP in 4 dogs (11%) and elevated cholesterol in 3 dogs (9%).
All dogs with hyperbilirubinaemia were stage 4 or 5. Five of 35 dogs had abnormalities detected on urine dipstick; bilirubinuria was observed in 4 dogs with hyperbilirubinaemia (11%) and proteinuria (defined as at least 2+ protein on dipstick analysis, in association with an unreactive urinary sediment, a urine specific gravity of less than 1.030, and the absence of haematuria) was seen in 3 dogs (9%).
Immunophenotyping was performed by flow cytometry in 
| Induction treatment and response
Twenty-seven dogs (60%) were treated with CHOP induction, vs 15 (33%) COP-type; 3 dogs (7%) had PD or death below 28 days, making them ineligible for placement in COP-type or CHOP treatment groups. Nine dogs (20%) were pretreated with l-asparaginase, 3 before a COP-type protocol and 6 before a CHOP protocol (median time before the protocol started was 1 day). Three dogs (7%) were pretreated with prednisolone (median time before protocol started 3 days). Haematology nadirs after chemotherapy treatments in the induction protocols were available for 25 dogs; of these, 14 dogs (56%) developed at least one episode of neutropenia, and the median neutropenia score for these dogs was 3 (range 1-13). A greater proportion of dogs from NDSR were induced with a CHOP protocol (80%) than RVC (60%), however, this difference was not statistically significant (P = .286).
The objective response rate to induction treatment was 93%; The 2 ratios which were found to have a significant effect on outcome have been marked in bold; NLR was independently predictive for PFS1 in (P = .025), and OS (P = .009). LMR was independently predictive of OS (P = .031).
Abbreviations: PFS1, progression-free survival for the first remission; OS, overall survival.
Thirty-seven dogs (82%) completed the induction protocol, 7 dogs (16%) had PD during induction treatment, and 1 dog's (2%) induction protocol was changed while it had a partial response to treatment due to the dog's aggressive behaviour.
| First remission PFS
Median PFS for the first remission (PFS1) was 182 days (95% confi- On multivariable analysis, only the absence of anaemia at diagnosis (P = .005) and treatment with a CHOP protocol over a COP-type protocol (P = .008) were found to be independently predictive of a longer PFS1. Table 3 . A greater proportion of dogs from RVC received rescue protocols (73% vs 40% from NDSR, P = .024).
The objective response rate to the first rescue protocol was 86%; 15 dogs (68%) achieved CR, 4 dogs (18%) achieved PR, 3 dogs followed by rescue protocols which contained doxorubicin, 2 dogs (5%) received COP-type induction followed by rescue protocols which did not contain doxorubicin, 9 dogs (21%) received CHOP induction followed by rescue protocols which contained doxorubicin, and 6 dogs (14%) received a CHOP induction followed by rescue protocols which did not contain doxorubicin.
The median number of treatment protocols received was 2(range 1-5). Thirty-seven dogs (82%) received doxorubicin at some point during their overall treatment, and the median number of doxorubicin doses was 4 (range 1-8; Table 4 ). The total number of doxorubicin doses did not differ significantly between dogs from RVC and NDSR (P = .259). The 3 dogs that were euthanased due to heart failure had a total number of 3, 4 and 5 doses of doxorubicin. No cardiotoxicity was seen in the 8 dogs that received more than 5 doses of doxorubicin (total dose exceeding 150 mg/m 2 ).
| Overall survival
The median OS for all dogs was 322 days (95% CI: 259-385 days).
No significant difference in OS was found between the 2 institutions (P = .366). OS was significantly shorter for large dogs (P = .010);
using an ROC (AUC 0.73) a cut-off value of 31.15 kg was found, with 82% sensitivity and 70% specificity for predicting OS of less than the median of 322 days. Dogs with a lower NLR (P = .047) and a higher LMR (P = .020) had a longer OS; using ROC analysis a LMR with a compared with CHOP induction alone (P = .04; Figure 5 ).
Overall, the number of doxorubicin doses (from 0 to 8) was highly significantly associated with longer OS (P = .000). When dogs that were not given doxorubicin were excluded from analysis, the strong association remained (P = .002, Table 5 ). Dogs that received 1 to 3 doses of doxorubicin had a median OS of 216 days (95% CI:
24-408 days), which was not significantly different to dogs that had 4 doses, equivalent to a complete CHOP protocol (median OS 322 days, 95% CI: 280-364 days, P = .777), but significantly shorter than dogs that had 5 to 8 doses (median OS 706 days, 95% CI: 297-1115 days, P = .049, Figure 6 ). On multivariable analysis, NLR (P = .009), LMR (P = .031), the combination of induction and rescue protocols (P = .030) and the number of doxorubicin doses (for the dogs that received doxorubicin, P = .002) were found to be independently predictive of OS. No other variables had a significant effect on OS.
| Prolonged and short survival groups
In this study, the 6-month survival rate was 73%, the 1-year survival rate was 38% and the 2-year survival rate was 9%. Dogs living more than 1 year had lower median bodyweight (mean 22.5 vs 31 kg, P = .019), were less likely to be anaemic on presentation (prevalence of anaemia at diagnosis of 11% vs 53%, P = .049), had a CR with induction therapy (100% vs 64%, P = .007) and when only the dogs that received doxorubicin were considered, those that received more doxorubicin doses were more likely to survive greater than 1 year (median number of 5 doxorubicin doses in dogs living greater than 1 year compared with 4 doses for those that lived less than 1 year, P = .031). Statistical analysis of dogs living longer than 2 years was not performed due to small group size.
Dogs with survivals of less than than 6 months had lower rates of CR with induction therapy (42% vs 91%, P = .001), were older (mean age of 9.5 vs 7.6 years, P = .031) and less likely to be treated with rescue therapy (27% receiving rescue vs 69% with no rescue, P = .031) than those that lived over 6 months.
| DISCUSSION
In this study, a homogenous population of mDLBCL-CB cases are described. The median PFS1 and OS of the whole group (182 and 322 days, respectively), and proportions surviving to 1 and 2 years (38% and 9%, respectively) were lower than 19, 55, 56 or similar to 57, 58 previous reports of groups containing mixed subtypes of multicentric CL. The OS of dogs in this study may not have been greater than that reported in mixed groups because many previous studies have been FIGURE 5 Kaplan-Meier curves of overall survival (OS, n = 28); combination of induction and rescue treatment was independently predictive of OS on Cox hazard regression (P = .030). In comparison with dogs that received CHOP induction followed by no rescue therapy, dogs that received a COP-type protocol with no rescue had an increased hazard ratio for death of 4.2 (P = .024), whereas dogs that received CHOP induction followed by doxorubicin-based rescue therapy had a reduced hazard ratio for death of 0.330 (P = .04). No significant differences were seen between dogs that received COPtype induction followed by doxorubicin-based rescue, dogs that received CHOP induction with no rescue protocol and dogs that received CHOP induction followed by a non-doxorubicin-based rescue protocol. The 2 dogs that received COP-type rescue after COP-type induction have been omitted from this graph for clarity.
[Colour figure can be viewed at wileyonlinelibrary.com] Hazard ratios (HR) are given for categories where significant differences in OS were found.
a Only 1 dog received 7 doses of doxorubicin hence the OS value is actual rather than median.
FIGURE 6
Kaplan-Meier curves of overall survival (OS, n = 37); the number of doses of doxorubicin received throughout induction and rescue therapy was independently predictive of OS on Cox hazard regression (P = .002). Compared with 1 to 3 doses of doxorubicin, dogs that received 5 to 8 doses had a decreased hazard ratio of death of 0.399 (P = .049). There was no statistically significant difference between dogs that received 4 doses and dogs that received 1 to 3 doses. [Colour figure can be viewed at wileyonlinelibrary.com] designed to evaluate a specific chemotherapy protocol, whereas this study evaluated a specific subtype of disease. A homogeneous population also lacks the potential influence of subtypes of disease that have much longer survival times, for example, T-zone lymphoma, 59 or shorter survival times, for example, lymphoblastic lymphomas. 23 The level of treatment a dog received varied in this study, including dogs that were given treatments which are not considered the "standard of care," prescribed for reasons such as finance or owner convenience. When specific combinations of induction and rescue therapy are evaluated, greater OS times are seen, for example, dogs that received CHOP induction followed by doxorubicin-based rescue had a median OS of 706 days (95% CI: 350-1062 days).
The response to induction treatment of mDLBCL-CB (objective response rate of 93%, complete response rate of 75.5%) was high. This rate has been similar in some studies 18, 58, 60 and lower in others. 19, 55, 56 Since mDLBCL-CB is the most prevalent type of lymphoma in dogs, 7 a level of similarity between this study group and a random selection of CL cases would be expected. Studies of mixed immunophenotype groups are likely to have included dogs with less responsive variants of the disease, for example, indolent lymphomas, that may not achieve complete responses. 59 In this study group, entire dogs had a significantly higher rate of complete responses to induction therapy; however, a greater proportion of entire dogs were treated with CHOP induction therapy than neutered dogs (73% vs 61%) and the low number of entire dogs (n = 11) throws the independence of this finding into question.
The presence of anaemia at diagnosis was shown to be associated with a significantly shorter PFS1 and was significantly more common in the group of dogs that survived less than 1 year, compared with dogs that survived over 1 year. The negative prognostic value of anaemia in CL has been demonstrated in previous studies, 36, 61 although the aetiology is unclear. Bone marrow infiltration by neoplastic lymphocytes has been hypothesized. However, one study found no significant difference in occurrence of marrow infiltration between groups of anaemic and non-anaemic dogs with lymphoma, and no significant difference in haematocrit between dogs with marrow involvement and those without. 61 Anaemia of inflammatory disease is another potential aetiology. A previous study has shown no laboratory evidence of this in a group of dogs with lymphoma, although decreased response of the bone marrow to erythropoietin is still possible. 62 The pathophysiological mechanism associating anaemia with a poor prognosis is unclear. One theory suggests that the state of chronic hypoxia may induce expression of proteins which enable cancer cells to deal better with stress; increased concentration of one such protein, vascular endothelial growth factor has been associated with a poorer prognosis in CL, 63 and both anaemia and a poorer prognosis in humans with NHL. 64 Choice of a CHOP induction protocol over a COP-type protocol was shown as independently prognostic for PFS1 in this study, in line with previous publications. 18 The superior PFS1 associated with the CHOP protocol may be related to both the longer duration of treatment and the use of another agent, doxorubicin. In agreement with other publications, 65, 66 this study found an association between the development of neutropenia and PFS1. Since data on the development of neutropenia were only available for fewer than half of the dogs, and the prevalence of neutropenia among these dogs was low,
we believe that assessment of the prognostic effect of neutropenia in this study was statistically under-powered. The prevalence of neutropenia may have been low because dogs induced with a COP-type protocol would have received a less immunosuppressive and shorter induction period compared with other studies, and because dose reductions were often performed following neutropenic episodes.
Response to the first rescue protocol (86%) and the median PFS2 (147 days) were similar to the response to induction therapy (94%) and the median PFS1 (182 days). Such findings have been described before. 67 For a number of dogs in this study group, the first rescue protocol can be regarded as "reinduction" since the median time between completing induction therapy and relapse was 118 days, making the development of appreciable drug resistance less likely. Additionally a number of dogs that were induced with a COP-type protocol received a doxorubicin-based rescue therapy. The response rates and remission durations associated with the second, third and fourth rescue protocols were more similar to previous reports of rescue treatment for lymphoma when drug-resistance is established. [68] [69] [70] [71] This study has shown the independent prognostic significance of the pretreatment NLR in predicting PFS and OS in canine mDLBCL-CB. Absolute leukocyte counts and their ratios are ways of measuring different aspects of systemic inflammation, and in cases of cancer systemic inflammation may be caused by tumour-related inflammation. 43 Tumour-related inflammation is associated with cancer progression 72 and in human medicine NLR has been recognized as holding prognostic significance in DLBCL, 41 and many solid tumours. 43 In veterinary medicine, NLR has been shown to be of some prognostic significance (on univariable but not multivariable analysis) in canine mast cell tumours. 73 Mutz et al recently reported no prognostic significance of NLR in a study of canine multicentric lymphoma treated with a CHOP protocol. 46 If the findings of our study are supported by subsequent work, the apparent disagreement with the study of Mutz et al may be due to an innate feature of mDLBCL-CB and the homogenous population of mDLBCL-CB cases in this study. Conversely, increased NLR is a very non-specific finding and despite screening dogs for concurrent disease, it is possible that the results are confounded by dogs with subclinical inflammatory conditions, for example, dental disease, otitis externa or pancreatitis.
We have reported that high NLR values (above a cut-off of 9.44 for PFS1 and 11.44 for OS), correspond to a poor prognosis. In human medicine, a cut-off value of 3.5 is established, above which DLBCL patients have both a significantly poorer PFS and OS. 41 High NLR cut-off values may make this test insensitive in veterinary medicine; however it may also reflect that neutrophilia and lymphopenia due to stress is more common in canine patients than humans, and so significant NLR levels will need to be in excess of that expected from a normal stress leukogram. Previous veterinary studies have evaluated absolute monocyte and lymphocyte counts in cancer; prognostic significance has been shown in canine osteosarcoma, 48 and in some studies of CL 44 but not others. 46 LMR has previously been reported as prognostic in human NHL, 74 in canine mast cell disease 73 and in CL. 45 This study concurs with the previous report of the prognostic significance of LMR for survival in mDLBCL-CB. However, just as for the significance of NLR, caution is needed in interpreting LMR values due to the non-specific aetiologies of its elevation.
This study has demonstrated that use of a rescue protocol, particularly rescue therapy involving doxorubicin, and the total number of doxorubicin doses received to be a strong prognostic factor in mDLBCL-CB cases. These observations should be interpreted with caution as many dogs that received a higher number of doses of doxorubicin are likely to be owned by the most committed owners, and subsequent doxorubicin treatments were unlikely to be offered would be meaningless, the discrepancy between the prognostic significance of LMR, response to induction therapy and the presence of anaemia at diagnosis for PFS1 vs OS is harder to explain. These findings may have arisen due to the population size and the effect of censoring some cases from OS analysis which were included in PFS1
analysis. Nevertheless if these findings hold true in larger populations one explanation could be that features such as some absolute cell concentration or ratios reflect the susceptibility of the disease to treatment at that point in time, thus they may be prognostic for length of the subsequent remission only, rather than for OS.
In this study, the authors feel justified in combining 2 different hospital populations since they are not significantly different in any key feature of clinical presentation or induction therapy, and their cytology has been reviewed by the same board-certified clinical pathologist. The only significant difference between the 2 groups is that a higher proportion of cases from RVC received a rescue protocol; we feel that this does not make the combination of populations any less valid since the choice of whether to use rescue therapy or not is dependent on the owners' wishes and finances, and it is not possible for these variables to be well controlled in retrospective studies. The finding of this study with regard to rescue therapy was that a response to rescue therapy is positively prognostic, and this is corroborated by other studies. 67 This study was limited by its retrospective nature and relatively small population size; resultantly the study is most likely underpowered and significant findings may have been missed. A large number of variables have also been statistically evaluated, giving the possibility that false positive associations have arisen by chance. Larger multi-institution studies are clearly needed to clarify this study's findings. The recruitment of cases from speciality referral centres might have also biased the caseload to those which had more complicated presentations, more likely to be of substage b, and with more committed owners. Although the study describes the response to different treatments, the authors caution that a retrospective study represents weak evidence to guide future therapeutic decisions. We hope that this study provides grounds for prospective, controlled trials in this area. Investigation of the genetic differences within this group of dogs may help to predict the dogs that will develop drug resistance sooner vs those will demonstrate prolonged response to therapy. 76 In conclusion, this study has shown the behaviour of disease and response to certain drugs in a population of dogs with mDLBCL-CB.
Absence of anaemia at diagnosis and a pretreatment NLR below 9.44
were associated with longer PFS1 while LMR above 1.43, and NLR below 11.44 were associated with longer OS. The use of rescue therapy and the number of doxorubicin doses received were strongly associated with longer OS. The choice of induction protocol did not influence survival, providing doxorubicin was later used as rescue therapy. Further, prospective studies are warranted to further assess the importance of these findings.
